Skip to main content
SpringerLink
Log in

Bedeutung des Arzneimittelmarktneuordnungsgesetzes für die Psychopharmakotherapie

Significance of the German Act on the Reform of the Market for Medicinal Products for psychopharmacotherapy

  • Leitthema
  • Published:
Der Nervenarzt Aims and scope Submit manuscript

Zusammenfassung

Das Arzneimittelmarktneuordnungsgesetz (AMNOG) wird dazu führen, dass in Deutschland in den nächsten Jahren neue Psychopharmaka rasch wieder vom Markt verschwinden oder erst gar nicht eingeführt werden. Dieser Beitrag führt die Gründe dafür an und zeigt Lösungsmöglichkeiten auf. Langfristig könnte das AMNOG – insbesondere wenn seine Maßstäbe internationaler Standard werden – nicht nur zu einer Verbesserung der Psychopharmakotherapie führen, sondern zu einer Weiterentwicklung des gesamten Faches beitragen.

Abstract

The German Act on the Reform of the Market for Medicinal Products (AMNOG) will lead to rapid disappearance of many new psychotropic drugs from the market in Germany over the next few years or their not being introduced in the first place. This article lists the reasons and discusses possible solutions. In the long term, the AMNOG could not only lead to an improvement of psychopharmacology but also contribute to the development of psychiatry as a whole, especially if its standards become an international reference.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1

Literatur

  1. Belzung C (2014) Innovative drugs to treat depression: did animal models fail to be predictive or did clinical trials fail to detect effects? Neuropsychopharmacology 39:1041–1051

    Article  PubMed  PubMed Central  Google Scholar 

  2. Flint J, Kendler KS (2014) The genetics of major depression. Neuron 81:484–503

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Fritze J (2015) Frühe Nutzenbewertung gemäß AMNOG: Rekapitulation und update. Psychopharmakotherapie 22:47–58

    Google Scholar 

  4. Goff DC (2015) Brexpiprazole: A new antipsychotic following in the footsteps of aripiprazole. Am J Psychiatry 172:820–821

    Article  PubMed  Google Scholar 

  5. Gründer G, Heinze M, Cordes J, Mühlbauer B, Juckel G, Schulz C, Rüther E, Timm J, NeSSy Study Group (2016) Effects of first- versus second-generation antipsychotics on quality of life in schizophrenia: a double-blind randomised study. Lancet Psychiatry (im Druck)

  6. Kishi T, Matsunaga S, Iwata N (2015) Suvorexant for primary insomnia: a systematic review and meta-analysis of randomized placebo-controlled trials. PLOS ONE 10:e0136910

    Article  PubMed  PubMed Central  Google Scholar 

  7. Klengel T, Binder EB (2013) Gene × environment interactions in the prediction of response to antidepressant treatment. Int J Neuropsychopharmacol 16:701–711

    Article  CAS  PubMed  Google Scholar 

  8. Lieberman JA, Stroup TS, McEvoy JP et al (2005) Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 353:1209–1223

    Article  CAS  PubMed  Google Scholar 

  9. Loebel A, Cucchiaro J, Silva R, Kroger H, Hsu J, Sarma K, Sachs G (2014) Lurasidone monotherapy in the treatment of bipolar I depression: a randomized, double-blind, placebo-controlled study. Am J Psychiatry 171:160–168

    Article  PubMed  Google Scholar 

  10. McGowan PO, Sasaki A, D’Alessio AC, Dymov S, Labonté B, Szyf M, Turecki G, Meaney MJ (2009) Epigenetic regulation of the glucocorticoid receptor in human brain associates with childhood abuse. Nat Neurosci 12:342–348

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Ripke S, Wray NR, Lewis CM, Major Depressive Disorder Working Group of the Psychiatric GWAS Consortium, - (2013) A mega-analysis of genome-wide association studies for major depressive disorder. Mol Psychiatry 18:497–511

    Article  CAS  PubMed  Google Scholar 

  12. Schulz C, Timm J, Cordes J, Gründer J, Mühlbauer B, Rüther E, Heinze M (2016) Patient-oriented randomisation: a new trial design applied in the NeSSy study. Clin Trials (im Druck)

  13. Spitzer RL, Fleiss JL (1974) A re-analysis of the reliability of psychiatric diagnosis. Br J Psychiatry 125:341–347

    Article  CAS  PubMed  Google Scholar 

  14. Stroup TS, Alves WM, Hamer RM, Lieberman JA (2006) Clinical trials for antipsychotic drugs: design conventions, dilemmas and innovations. Nat Rev Drug Discov 5:133–146

    Article  CAS  PubMed  Google Scholar 

  15. Stroup TS, Lieberman JA, McEvoy JP et al (2007) CATIE Investigators. Effectiveness of olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia after discontinuing perphenazine: a CATIE study. Am J Psychiatry 164:415–427

    Article  PubMed  Google Scholar 

  16. Thase ME (2013) The multifactorial presentation of depression in acute care. J Clin Psychiatry 74(Suppl 2):3–8

    Article  PubMed  Google Scholar 

  17. van Loo HM, de Jonge P, Romeijn JW, Kessler RC, Schoevers RA (2012) Data-driven subtypes of major depressive disorder: a systematic review. BMC Med 10:156

    Article  PubMed  PubMed Central  Google Scholar 

  18. Veselinović T, Paulzen M, Gründer G (2013) Cariprazine, a new, orally active dopamine D2/3 receptor partial agonist for the treatment of schizophrenia, bipolar mania and depression. Expert Rev Neurother 13:1141–1159

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Klinik für Psychiatrie, Psychotherapie und Psychosomatik, Uniklinik RWTH Aachen, Pauwelsstr. 30, 52074, Aachen, Deutschland

    G. Gründer

Authors
  1. G. Gründer
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to G. Gründer.

Ethics declarations

Interessenkonflikt

G. Gründer war als Berater bzw. in Advisory Boards der folgenden Firmen tätig: Boehringer Ingelheim (Ingelheim, Deutschland), Cheplapharm (Greifswald, Deutschland), Eli Lilly (Indianapolis, Ind, USA), Lundbeck (Kopenhagen, Dänemark), Ono Pharmaceuticals (Osaka, Japan), Roche (Basel, Schweiz), Servier (Paris, Frankreich), Takeda (Osaka, Japan). Er war als Referent tätig für Eli Lilly, Gedeon Richter (Budapest, Ungarn), Janssen Cilag (Neuss, Deutschland), Lundbeck, Roche, Servier, und Trommsdorf (Aachen, Deutschland). Er hat Forschungsprojekte mit Boehringer Ingelheim und Roche durchgeführt. Er ist Mitgründer und Teilhaber von Pharma Image GmbH (Düsseldorf, Deutschland) und Brainfoods UG (Selfkant, Deutschland).

Dieser Beitrag beinhaltet keine vom Autor durchgeführten Studien an Menschen oder Tieren.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Gründer, G. Bedeutung des Arzneimittelmarktneuordnungsgesetzes für die Psychopharmakotherapie. Nervenarzt 87, 356–366 (2016). https://doi.org/10.1007/s00115-016-0095-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00115-016-0095-z

Schlüsselwörter

Keywords

Search

Navigation